Communiqués Veru Inc.

Actions

VERU

US92536C2026

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 06/10/2026			Varia. 5j.	Varia. 1 janv.
2,470 ^USD	-3,14%		-3,52%	+15,42%

08/09	Veru fait progresser la sabizabuline par voie orale vers un essai clinique de phase 2 pour le cancer du pancréas métastatique résistant au daraxonrasib	CI
10/08	Transcript : Veru Inc., Q3 2026 Earnings Call, Aug 10, 2026

Communiqués

08/09	Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial	AQ
02/09	Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference	AQ
10/08	Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress	AQ
04/08	Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss	AQ
03/08	Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th	AQ
30/07	Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference	AQ
27/07	Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	AQ
07/07	Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day	AQ
13/05	Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress	AQ
06/05	Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th	AQ
09/03	Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	AQ
02/03	Veru : Corporate Presentation, February 2026	PU
19/02	Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
11/02	Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress	AQ
04/02	Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th	AQ
21/01	Veru : JPM 2026	PU
18/12	Veru : Annual Report for Fiscal Year Ending 09-30, 2025 (Form 10-K)	PU
17/12	Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress	AQ
10/12	Veru to Report Fiscal Year 2025 Financial Results on December 17th	AQ
04/12	Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop	AQ
19/11	Veru : Corporate Presentation, November 2025	PU
31/10/25	Veru to Present Two Abstracts at ObesityWeek 2025	AQ
30/10/25	Veru Announces Pricing of $25 Million Public Offering	AQ
29/10/25	Veru Announces Proposed Public Offering	AQ
16/10/25	Veru : Corporate Presentation, October 2025	PU